More Articles

Celltrion applies for biosimilar infliximab approval in Japan Biosimilars/News | Posted 13/09/2013

On 11 September 2013, South Korean biotechnology company Celltrion announced that it had filed for approval of Remsima, its biosimilar infliximab monoclonal antibody, with Japan’s Ministry of Healt...

Ranbaxy to expand Russian portfolio Generics/News | Posted 13/09/2013

Generics manufacturer Ranbaxy Laboratories (Ranbaxy) has been in the Russian pharmaceuticals market for 20 years and is now considering expanding its product offering in the country.

India’s pharma moving from generics to niche drugs Reports | Posted 13/09/2013

Indian pharmaceutical companies will increasingly move away from the overcrowded and competitive area of generics and invest more R & D spending in niche drugs, according to a new report.

Akorn to buy Hi-Tech Pharmacal for US$640 million Pharma News | Posted 13/09/2013

Generic eye-drugmaker Akorn has entered into a deal to buy Hi-Tech Pharmacal (Hi-Tech) for US$640 million in cash to expand into oral liquids and ointments, including cold and cough treatments.

Therapeutic substitution could save Americans money Generics/Research | Posted 06/09/2013

Substituting more expensive brand-name drugs with generics or therapeutic substitutes, could lead to significant savings for Medicare Part D beneficiaries, according to US researchers [1].

Positive phase III data for Epirus infliximab biosimilar Biosimilars/Research | Posted 06/09/2013

US-based Epirus Biopharmaceuticals (Epirus) announced on 28 August 2013 that its biosimilar infliximab candidate had demonstrated ‘clinical comparability’ to Remicade as measured by the ACR20 respo...

Authorized generics reduce drug prices Reports | Posted 06/09/2013

In what seems to be a bit of a turnaround for the US Federal Trade Commission (FTC), the agency has released a report which suggests that authorized generics can reduce both retail and wholesale dr...

Biocad signs deal for biosimilar darbepoetin alpha in Turkey Biosimilars/News | Posted 06/09/2013

Russian biosimilars manufacturer Biocad has signed a definitive agreement with Turkish oncology specialist Koçak Farma for the export of biosimilar darbepoetin alpha active pharmaceutical ingredien...